SGHT: Q2 revenue up 20% YoY, guidance raised, and strong growth in both glaucoma and dry eye segments
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw 20% revenue growth, record performance in both interventional segments, and improved margins. Full-year guidance was raised, cash usage dropped, and new product launches and payer wins support continued momentum.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw 20% revenue growth, record performance in both interventional segments, and improved margins. Full-year guidance was raised, cash usage dropped, and new product launches and payer wins support continued momentum.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.